Private company · employee equity guide
What is Immunai stock worth?
Comprehensively mapping and decoding the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development and improve patient outcomes
Estimated share price
Immunai has an observed estimated price: most recent data 2026-07-29, daily history back to 2026-06-09.
Estimated from observed bids, offers, and closed transactions on a leading secondary marketplace. Private shares are illiquid and transfer-restricted; estimates are educational, not an offer or advice. How this is calculated
About Immunai
- Employees
- 176
- Founded
- 2019
- Website
- immunai.com
Weighing a Immunai offer?
Upload the offer letter to see what the equity is approximately worth at today's estimated price. No account needed.
X-ray an offerLeaving Immunai? Mind the window.
If you hold options, leaving usually starts a post-termination exercise clock, often 90 days. Miss it and vested options can expire worthless; exercise blindly and you may owe real money (including possible AMT) on shares you can't yet sell. Neither panic nor autopilot is a plan. Knowing your window, your exercise cost, and the current estimated price is.
Immunai equity, answered plainly
Is Immunai a public company?
No. Immunai is privately held, which is exactly why its share price doesn't show up in your brokerage app. Its shares still change hands between eligible buyers and sellers on the secondary market, producing an observable estimated price.
What is Immunai's stock price?
Immunai has an observed estimated share price from secondary-market activity, updated as new data is observed. ExitCue members see the current estimate and its full history free, along with what their own grants are approximately worth at that price.
Can you sell Immunai stock before an IPO?
Sometimes. Private-share sales depend on Immunai's transfer restrictions, rights of first refusal, and whether the company runs tender offers or permits secondary sales. Your grant documents and the company's policies govern, but "hard to sell today" is not the same as "worth zero."
What happens to my Immunai options if I leave?
Most option grants have a post-termination exercise window, commonly 90 days, sometimes longer, after which unexercised options expire worthless. The exact terms are in your grant documents. ExitCue reads those documents, tracks the deadline, and reminds you before the window closes.
How much is my Immunai equity worth?
Multiply what you hold by the estimated share price, separating vested from unvested, and netting out strike prices for options. That's precisely the arithmetic ExitCue does for you, continuously, at the current observed estimate. It's an educational estimate, not a guarantee, and a far better anchor than the $0 the internet suggests.
What's the difference between Immunai's 409A valuation and what its shares trade at?
The 409A is a tax-compliance appraisal, usually conservative, used to set option strike prices. Secondary-market pricing reflects what buyers and sellers actually agree to. The two frequently differ, which is why evaluating an offer on the 409A alone undersells (or oversells) it.
When will Immunai IPO?
Unless Immunai has publicly announced a listing, nobody knows, including the people who sound confident on forums. The practical upside of secondary markets is that you don't have to wait for an IPO to know approximately what the shares trade at.
Do my unvested Immunai RSUs count for anything?
Unvested equity isn't yours yet, but it has an estimable value and a schedule. Seeing vested and unvested value separately, in dollars at the current estimated price, turns "some RSUs" into a number you can plan around.
General educational information, not advice about your specific situation. Grant terms vary; your documents govern.